XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Concentration Risk [Line Items]          
Rebate receivable $ 45,900   $ 45,900   $ 52,000
Investments in equity-method investees 23,600   23,600   $ 20,900
Proportionate share of earnings in equity-method investees $ 1,400 $ 1,300 3,921 $ 4,107  
Distributions received from the investees     $ 1,250 $ 4,000  
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 11.00% 11.00% 12.00% 12.00%  
Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent)     10.00%   12.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 68.00% 73.00% 67.00% 73.00%  
Largest Payer | Revenue from Contract with Customer Benchmark | Company's Largest Payer          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 15.00% 14.00% 15.00% 14.00%  
Joint Venture          
Concentration Risk [Line Items]          
Distributions received from the investees $ 500 $ 1,500 $ 1,300 $ 4,000